Coronavirus Immunotherapy Consortium (IMAGE)
Caption
Headquartered at LJI, CoVIC will serve as a clearinghouse to understand which antibodies are most effective against the novel coronavirus SARS-CoV-2 and to accelerate the research pipeline to provide immunotherapeutics in order to protect vulnerable individuals from severe manifestations of COVID-19 in all parts of the world including low-resource settings.
Credit
La Jolla Institute for Immunology/CoVIC
Usage Restrictions
None
License
Licensed content